# 68Ga-P16-093 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI

> **NCT07209865** · PHASE1,PHASE2 · RECRUITING · sponsor: **First Affiliated Hospital of Fujian Medical University** · enrollment: 50 (estimated)

## Conditions studied

- Prostate Cancer (Adenocarcinoma)

## Interventions

- **DRUG:** 68Ga-P16-093

## Key facts

- **NCT ID:** NCT07209865
- **Lead sponsor:** First Affiliated Hospital of Fujian Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-06-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07209865

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07209865, "68Ga-P16-093 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07209865. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*